Change in estimated glomerular filtration rate and outcomes in chronic kidney disease

被引:5
作者
Ferguson, Thomas W. [1 ,2 ]
Komenda, Paul [1 ,2 ]
Tangri, Navdeep [1 ,2 ]
机构
[1] Univ Manitoba, Fac Hlth Sci, Nephrol Sect, Dept Med, Winnipeg, MB R3T 2N2, Canada
[2] Seven Oaks Hosp Winnipeg, Chron Dis Innovat Ctr, Winnipeg, MB, Canada
关键词
chronic kidney disease; glomerular filtration rate; kidney failure; mortality; serum creatinine; CLINICAL-TRIALS; GFR DECLINE; END-POINT; CKD;
D O I
10.1097/MNH.0000000000000210
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Estimated glomerular filtration rate (eGFR) is important in the diagnosis and prognostication of chronic kidney disease (CKD). The current standards for CKD progression in clinical trials are kidney failure and the doubling of serum creatinine (similar to 57% decline in eGFR). These endpoints have limitations as they are only applicable to patients with later stages of CKD and often require large sample sizes to achieve adequate power. Recent findings Lesser declines in eGFR (30% and 40%) have been evaluated as potential endpoints in recent studies. These endpoints are more common and show a strong association with the risk of end-stage renal disease and mortality. These findings have been shown to be consistent across different causes of CKD and for different interventions. A particular limitation of reduced thresholds is an elevated risk of type I errors in the presence of acute treatment effects, particularly with a 30% eGFR decline cut off. Summary Surrogate endpoints for kidney failure and mortality are needed in clinical trials to allow for the reasonable management of timelines and resources, and the achievement of adequate sample sizes. Lesser eGFR decline thresholds should be considered to aid in the design and conduct of more randomized controlled trials in nephrology.
引用
收藏
页码:240 / 244
页数:5
相关论文
共 18 条
  • [1] Glomerular filtration rate decline as a surrogate end point in kidney disease progression trials
    Badve, Sunil V.
    Palmer, Suetonia C.
    Hawley, Carmel M.
    Pascoe, Elaine M.
    Strippoli, Giovanni F. M.
    Johnson, David W.
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2016, 31 (09) : 1425 - 1436
  • [2] Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy
    Brenner, BM
    Cooper, ME
    de Zeeuw, D
    Keane, WF
    Mitch, WE
    Parving, HH
    Remuzzi, G
    Snapinn, SM
    Zhang, ZX
    Shahinfar, S
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) : 861 - 869
  • [3] Decline in Estimated Glomerular Filtration Rate and Subsequent Risk of End-Stage Renal Disease and Mortality
    Coresh, Josef
    Turin, Tanvir Chowdhury
    Matsushita, Kunihiro
    Sang, Yingying
    Ballew, Shoshana H.
    Appel, Lawrence J.
    Arima, Hisatomi
    Chadban, Steven J.
    Cirillo, Massimo
    Djurdjev, Ognjenka
    Green, Jamie A.
    Heine, Gunnar H.
    Inker, Lesley A.
    Irie, Fujiko
    Ishani, Areef
    Ix, Joachim H.
    Kovesdy, Csaba P.
    Marks, Angharad
    Ohkubo, Takayoshi
    Shalev, Varda
    Shankar, Anoop
    Wen, Chi Pang
    de Jong, Paul E.
    Iseki, Kunitoshi
    Stengel, Benedicte
    Gansevoort, Ron T.
    Levey, Andrew S.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (24): : 2518 - 2531
  • [4] Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization
    Go, AS
    Chertow, GM
    Fan, DJ
    McCulloch, CE
    Hsu, CY
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (13) : 1296 - 1305
  • [5] Lifetime Incidence of CKD Stages 3-5 in the United States
    Grams, Morgan E.
    Chow, Eric K. H.
    Segev, Dorry L.
    Coresh, Josef
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2013, 62 (02) : 245 - 252
  • [6] Utility and Validity of Estimated GFR-Based Surrogate Time-to-Event End Points in CKD: A Simulation Study
    Greene, Tom
    Teng, Chia-Chen
    Inker, Lesley A.
    Redd, Andrew
    Ying, Jian
    Woodward, Mark
    Coresh, Josef
    Levey, Andrew S.
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2014, 64 (06) : 867 - 879
  • [7] GFR Decline and Subsequent Risk of Established Kidney Outcomes: A Meta-analysis of 37 Randomized Controlled Trials
    Heerspink, Hiddo J. Lambers
    Tighiouart, Hocine
    Sang, Yingying
    Ballew, Shoshana
    Mondal, Hasi
    Matsushita, Kunihiro
    Coresh, Josef
    Levey, Andrew S.
    Inker, Lesley A.
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2014, 64 (06) : 860 - 866
  • [8] GFR Decline as an Alternative End Point to Kidney Failure in Clinical Trials: A Meta-analysis of Treatment Effects From 37 Randomized Trials
    Inker, Lesley A.
    Heerspink, Hiddo J. Lambers
    Mondal, Hasi
    Schmid, Christopher H.
    Tighiouart, Hocine
    Noubary, Farzad
    Coresh, Josef
    Greene, Tom
    Levey, Andrew S.
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2014, 64 (06) : 848 - 859
  • [9] Past Decline Versus Current eGFR and Subsequent ESRD Risk
    Kovesdy, Csaba P.
    Coresh, Josef
    Ballew, Shoshana H.
    Woodward, Mark
    Levin, Adeera
    Naimark, David M. J.
    Nally, Joseph
    Rothenbacher, Dietrich
    Stengel, Benedicte
    Iseki, Kunitoshi
    Matsushita, Kunihiro
    Levey, Andrew S.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2016, 27 (08): : 2447 - 2455
  • [10] GFR Decline as an End Point for Clinical Trials in CKD: A Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration
    Levey, Andrew S.
    Inker, Lesley A.
    Matsushita, Kunihiro
    Greene, Tom
    Willis, Kerry
    Lewis, Edmund
    de Zeeuw, Dick
    Cheung, Alfred K.
    Coresh, Josef
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2014, 64 (06) : 821 - 835